Vertex EVP uses 3,548 shares for tax withholding

Q: What insider transaction did Vertex (VRTX) executive Amit Sachdev report?

Amit Sachdev reported a tax-withholding disposition of 3,548 Vertex common shares at $487.76 per share on February 13, 2026. This transaction satisfied tax obligations rather than representing an open-market purchase or sale.

Q: How many Vertex (VRTX) shares does Amit Sachdev hold after this Form 4?

After the reported transaction, Amit Sachdev directly held 65,393 Vertex shares. He also had indirect ownership of 9,301 shares held in a trust and 882 shares in a 401(k), according to the Form 4 disclosure.

Q: Was the Vertex (VRTX) Form 4 transaction a sale on the open market?

The Form 4 characterizes the transaction as a tax-withholding disposition, not an open-market sale. Code F indicates payment of tax liability by delivering already-held securities instead of selling shares in a market trade.

Q: What transaction code was used in Amit Sachdev’s Vertex (VRTX) Form 4?

The filing uses transaction code F, described as “Payment of exercise price or tax liability by delivering securities.” This means shares were used to cover tax obligations tied to equity compensation, rather than a discretionary buy or sell.

Q: How many Vertex (VRTX) shares were involved in the tax-withholding disposition?

The tax-withholding disposition involved 3,548 shares of Vertex common stock at a reported price of $487.76 per share. These shares were delivered to satisfy tax obligations associated with equity awards, as disclosed in the Form 4.

Q: What indirect Vertex (VRTX) holdings does Amit Sachdev report on Form 4?

The Form 4 lists 9,301 Vertex shares held in a trust and 882 shares in a 401(k) as indirect holdings. These positions are reported separately from his 65,393 directly held shares of Vertex common stock.

Vertex Pharmaceuticals executive Amit Sachdev, EVP Chief Patient & External Affairs Officer, disposed of 3,548 shares of common stock on February 13, 2026 at $487.76 per share in a tax-withholding disposition.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Amit Sachdev, EVP Chief Patient & External Affairs Officer, disposed of 3,548 shares of common stock on February 13, 2026 at $487.76 per share in a tax-withholding disposition. After this, he directly held 65,393 shares, with additional indirect holdings of 9,301 shares in a trust and 882 shares in a 401(k).

Insider Trade Summary

Exercise Price or Tax Liability: 3,548 shares

Exercise Price or Tax Liability 3 txns

Insider Sachdev Amit

Role EVP Chief Patient & Ext Af Off

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	3,548	$487.76	$1.73M
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 65,393 shares (Direct); Common Stock — 9,301 shares (Indirect, Held in Trust); Common Stock — 882 shares (Indirect, 401(k))

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Vertex (VRTX) executive Amit Sachdev report?

Amit Sachdev reported a tax-withholding disposition of 3,548 Vertex common shares at $487.76 per share on February 13, 2026. This transaction satisfied tax obligations rather than representing an open-market purchase or sale.

How many Vertex (VRTX) shares does Amit Sachdev hold after this Form 4?

After the reported transaction, Amit Sachdev directly held 65,393 Vertex shares. He also had indirect ownership of 9,301 shares held in a trust and 882 shares in a 401(k), according to the Form 4 disclosure.

Was the Vertex (VRTX) Form 4 transaction a sale on the open market?

The Form 4 characterizes the transaction as a tax-withholding disposition, not an open-market sale. Code F indicates payment of tax liability by delivering already-held securities instead of selling shares in a market trade.

What transaction code was used in Amit Sachdev’s Vertex (VRTX) Form 4?

The filing uses transaction code F, described as “Payment of exercise price or tax liability by delivering securities.” This means shares were used to cover tax obligations tied to equity compensation, rather than a discretionary buy or sell.

How many Vertex (VRTX) shares were involved in the tax-withholding disposition?

The tax-withholding disposition involved 3,548 shares of Vertex common stock at a reported price of $487.76 per share. These shares were delivered to satisfy tax obligations associated with equity awards, as disclosed in the Form 4.

What indirect Vertex (VRTX) holdings does Amit Sachdev report on Form 4?

The Form 4 lists 9,301 Vertex shares held in a trust and 882 shares in a 401(k) as indirect holdings. These positions are reported separately from his 65,393 directly held shares of Vertex common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/18/2026 - 04:39 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sachdev Amit

(Last)

(First)

(Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON

02210

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP Chief Patient & Ext Af Off

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/13/2026		F		3,548	D	$487.76	65,393	D
Common Stock								9,301	I	Held in Trust
Common Stock								882	I	401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR